Transfection of interleukin 2 gene into human melanoma cells augments cellular immune response.
A preclinical model was used to determine if transfection of the interleukin 2 (IL-2) gene into human melanoma cells would augment the response of autologous and allogeneic peripheral blood lymphocytes (PBLs) from melanoma patients. IL-2 gene was transfected into three human melanoma cell lines; secretion of IL-2 from stable transfected cells was confirmed by enzyme-linked immunosorbent assay. The PBL response to these melanoma cells was then examined in a mixed-lymphocyte tumor reaction using PBLs from eight melanoma patients. The PBL response to autologous (P < 0.01) or human leukocyte antigen A cross-reactive (P < 0.05) transfected melanoma cells was significantly higher than it was to nontransfected melanoma cells. These data suggest that IL-2 gene transfection may be an important strategic approach to enhancing specific immune responses induced by a polyvalent melanoma cell vaccine.
Uchiyama
A
A
John Wayne Cancer Institute, Santa Monica, California 90404.
Hoon
D S
DS
Morisaki
T
T
Kaneda
Y
Y
Yuzuki
D H
DH
Morton
D L
DL
D001483:Base Sequence; D015316:Genetic Therapy; D015234:HLA-A Antigens / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular; D007167:Immunotherapy; D007376:Interleukin-2 / Q000235:genetics*; D008545:Melanoma / Q000276:immunology* / Q000628:therapy; D008969:Molecular Sequence Data; D014162:Transfection; D014407:Tumor Cells, Cultured
D015234:HLA-A Antigens; D007376:Interleukin-2